By a GenomeWeb staff reporter

NEW YORK (Genomeweb News) – Enzo Biochem today said that a decision by an appellate court last week that reversed a district court's summary judgment enables the firm to pursue a claim for "substantial damages" against Life Technologies.

Enzo said that the Court of Appeals for the Federal Circuit had vacated the lower court's judgment of invalidity for US Patent Nos. 5,328,824 and 5,449,767.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.